# A novel candidate biomarker for detecting premalignant and early ovarian cancer

Source: [nature.com](https://www.nature.com/articles/s41591-026-04755-2) · 2026-11-10 · Medicine
Page: https://themorning.science/story/a-novel-candidate-biomarker-for-detecting-premalignant-and-early-ovarian-cancer-78d4b6ec0ee06f76
Kind: research · Impact: medium

## In brief

- A Nature Medicine study reports that the long noncoding RNA Tu-Stroma, measured in blood, may serve as a circulating biomarker for detecting premalignant and early ovarian cancer.
- The biomarker was tested in a cohort of 506 individuals and reportedly discriminates early-stage ovarian cancer from benign lesions with high performance.
- Two related articles on nature.com were published online on 10 November 2026 with different DOIs describing the same candidate biomarker.

## Why it matters

Ovarian cancer is often detected late, and a blood-based test for premalignant and early disease could enable earlier intervention if validated in larger, independent studies.

## Timeline

- 2026-11-10: Study describing Tu-Stroma blood-based RNA biomarker for early ovarian cancer detection published online in Nature Medicine

## Coverage

- [A novel candidate biomarker for detecting premalignant and early ovarian cancer](https://www.nature.com/articles/s41591-026-04755-2) — nature.com, 2026-11-10
- [Blood-based RNA biomarker for the early detection of ovarian cancer](https://www.nature.com/articles/s41591-026-04732-9) — nature.com, 2026-11-10

Tags: ovarian cancer, biomarker, liquid biopsy, long noncoding rna, early detection

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science